Katherine R. Tuttle

665 total papers · 41.3k total citations
303 papers, 19.5k citations indexed

About

Katherine R. Tuttle is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Surgery. According to data from OpenAlex, Katherine R. Tuttle has authored 303 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Endocrinology, Diabetes and Metabolism, 117 papers in Nephrology and 68 papers in Surgery. Recurrent topics in Katherine R. Tuttle's work include Diabetes Treatment and Management (129 papers), Chronic Kidney Disease and Diabetes (90 papers) and Diabetes Management and Research (46 papers). Katherine R. Tuttle is often cited by papers focused on Diabetes Treatment and Management (129 papers), Chronic Kidney Disease and Diabetes (90 papers) and Diabetes Management and Research (46 papers). Katherine R. Tuttle collaborates with scholars based in United States, Canada and Denmark. Katherine R. Tuttle's co-authors include Radica Z. Alicic, Michele T. Rooney, Ian H. de Boer, George L. Bakris, Robert Short, Richard J. Johnson, Maryam Afkarian, Joshua J. Neumiller, Irl B. Hirsch and Peter Rossing and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Katherine R. Tuttle

280 papers receiving 18.9k citations

Hit Papers

Diabetic Kidney Disease 2000 2026 2008 2017 2017 2003 2000 2013 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Diabetic Kidney Disease
    2017 1.8k citations Radica Z. Alicic, Michele T. Rooney et al. Clinical Journal of the American Society of Nephrology profile →
  2. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
    2003 1.1k citations Richard J. Johnson, Duk‐Hee Kang et al. Hypertension profile →
  3. Preserving renal function in adults with hypertension and diabetes: A consensus approach
    2000 1.1k citations George L. Bakris, Mark E. Williams et al. American Journal of Kidney Diseases profile →
  4. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
    2013 898 citations Maryam Afkarian, Michael C. Sachs et al. Journal of the American Society of Nephrology profile →
  5. A causal role for uric acid in fructose-induced metabolic syndrome
    2005 854 citations Takahiko Nakagawa, Hanbo Hu et al. American Journal of Physiology-Renal Physiology profile →
  6. Diabetic Kidney Disease: A Report From an ADA Consensus Conference
    2014 776 citations Katherine R. Tuttle, George L. Bakris et al. Diabetes Care profile →
  7. Diabetic Kidney Disease: A Report From an ADA Consensus Conference
    2014 665 citations Katherine R. Tuttle, George L. Bakris et al. American Journal of Kidney Diseases profile →
  8. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
    2016 661 citations Maryam Afkarian, Leila R. Zelnick et al. JAMA profile →
  9. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
    2022 610 citations Ian H. de Boer, Peter Rossing et al. Kidney International profile →
  10. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    2024 605 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
  11. Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis
    2013 520 citations Christopher J. Cooper, Timothy P. Murphy et al. New England Journal of Medicine profile →
  12. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
    2018 450 citations Katherine R. Tuttle, Mark Lakshmanan et al. The Lancet Diabetes & Endocrinology profile →
  13. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 366 citations Ian H. de Boer, Kamlesh Khunti et al. Diabetes Care profile →
  14. Molecular mechanisms and therapeutic targets for diabetic kidney disease
    2022 328 citations Katherine R. Tuttle, Rajiv Agarwal et al. Kidney International profile →
  15. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
    2023 258 citations Sadiya S. Khan, Josef Coresh et al. Circulation profile →
  16. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    2022 170 citations Hiddo J.L. Heerspink, Naveed Sattar et al. The Lancet Diabetes & Endocrinology profile →
  17. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 161 citations Ian H. de Boer, Kamlesh Khunti et al. Kidney International profile →
  18. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
    2023 143 citations Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation profile →
  19. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 96 citations Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine profile →
  20. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    2024 72 citations Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology profile →
  21. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
    2024 70 citations Johannes F.E. Mann, Peter Rossing et al. Nature Medicine profile →
  22. Combination therapy for kidney disease in people with diabetes mellitus
    2024 43 citations Daniël H. van Raalte, Petter Bjornstad et al. Nature Reviews Nephrology profile →
  23. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
    2024 43 citations Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology profile →
  24. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    2024 41 citations Brendon L. Neuen, Robert A. Fletcher et al. Circulation profile →
  25. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
    2025 16 citations Katherine R. Tuttle, Imre Pávó et al. Diabetes Care profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Katherine R. Tuttle 8.4k 7.4k 3.6k 3.5k 3.3k 303 19.5k
Merlin C. Thomas 6.1k 0.7× 4.1k 0.6× 4.2k 1.2× 2.5k 0.7× 3.5k 1.0× 351 18.7k
Michael W. Steffes 7.2k 0.9× 5.6k 0.7× 2.4k 0.6× 4.2k 1.2× 3.4k 1.0× 154 19.6k
Ian H. de Boer 6.5k 0.8× 7.7k 1.0× 2.4k 0.7× 3.1k 0.9× 3.8k 1.1× 324 20.0k
Hans‐Henrik Parving 8.9k 1.1× 7.4k 1.0× 2.8k 0.8× 2.2k 0.6× 8.5k 2.5× 232 20.8k
David C. Wheeler 6.1k 0.7× 6.8k 0.9× 2.5k 0.7× 3.9k 1.1× 2.8k 0.8× 271 16.1k
Ron T. Gansevoort 4.7k 0.6× 11.5k 1.5× 4.6k 1.3× 3.1k 0.9× 7.0k 2.1× 463 26.6k
Robert C. Atkins 3.9k 0.5× 7.6k 1.0× 2.8k 0.8× 2.0k 0.6× 4.3k 1.3× 242 18.3k
Andrzej S. Królewski 5.7k 0.7× 5.2k 0.7× 3.1k 0.9× 3.2k 0.9× 2.5k 0.8× 190 15.6k
William F. Keane 5.1k 0.6× 8.1k 1.1× 2.0k 0.6× 2.5k 0.7× 6.4k 1.9× 186 17.8k
Per‐Henrik Groop 9.7k 1.2× 3.5k 0.5× 5.8k 1.6× 4.4k 1.2× 3.7k 1.1× 524 23.0k

Countries citing papers authored by Katherine R. Tuttle

Since Specialization
Citations

This map shows the geographic impact of Katherine R. Tuttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine R. Tuttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine R. Tuttle more than expected).

Fields of papers citing papers by Katherine R. Tuttle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine R. Tuttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine R. Tuttle. The network helps show where Katherine R. Tuttle may publish in the future.

Co-authorship network of co-authors of Katherine R. Tuttle

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine R. Tuttle. A scholar is included among the top collaborators of Katherine R. Tuttle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine R. Tuttle. Katherine R. Tuttle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rhoda Au Breakdown of academic impact, for papers by William Breitbart Breakdown of academic impact, for papers by Mallikarjuna N. Nadagouda Breakdown of academic impact, for papers by Benedetto Vitiello Breakdown of academic impact, for papers by Bruce J. Brew Breakdown of academic impact, for papers by Gianluigi Condorelli Breakdown of academic impact, for papers by Alan N. Schechter Breakdown of academic impact, for papers by Arthur C. Ouwehand
Rankless by CCL
2026